Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

from Eli Lilly before 27 September. Novartis and Amgen already have a CGRP drug on the market – Aimovig (erenumab) was approved in the US in May. Teva has priced its monthly injection at $575 ...

Teva saw its revenue fall by 5% in the fourth ... The revenue increase leaders of the fourth quarter were familiar—Eli Lilly (45%) and Novo Nordisk (30%). For both companies, the increases ...

Eli Lilly said Wednesday it will invest $27 billion to build four new manufacturing plants in the United States as the pharmaceutical giant grapples with the threat of drug import duties from the ...

Teva and Alvotech have been working together ... of Weight-Loss Drug Wegovy for Some Patients Paying Out of Pocket Eli Lilly Cuts Price of Weight-Loss Drug Zepbound for Self-Pay Patients AbbVie ...

Eli Lilly and Co. Wednesday announced plans to build four pharmaceutical manufacturing sites in the United States, significantly boosting domestic medicine production and adding around 13,000 ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

Lilly is launching two new doses and cutting prices for self-paying customers Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and ...

A major pharmaceutical company that has invested heavily in North Carolina is planning multiple new factories in the U.S. STORY HIGHLIGHTS Eli Lilly plans $27 billion U.S. expansion, will create ...